-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

Benzinga·07/29/2026 15:50:36
语音播报
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.